文献速递前列腺癌肾癌与肾肿瘤膀胱癌与上尿路尿路上皮癌

在泌尿生殖系统肿瘤中利用第三方合作开展远程遗传风险评估项目

Utilization of a Third-party Partnership in Tele-genetic Risk Assessment Program in Genitourinary Oncology.
PubMed 文献 · Urology · 2024-05-23

为满足因临床指南扩展而增加的泌尿生殖系统肿瘤遗传风险评估需求,研究建立学术与产业合作流程。2020年1月1日至2022年1月7日,182例患者中146例(80.0%)同意参与,130例(89.0%)完成检测前咨询,中位年龄65岁(范围22-95),91%为男性,约60%患前列腺癌。结论认为该模式患者满意度高、遗传咨询和检测可及快、结果发布及时,且与传统模式相比具有成本效益。

要点

  • 182例中146例(80.0%)同意参与,130例(89.0%)完成检测前咨询。
  • 127例(97.7%)被推荐检测,其中123例(96.8%)完成检测。
  • 患者满意度高,遗传咨询师满意度量表平均27.9分(满分30分)。

核心结论

  • 本合作项目患者满意度高、遗传咨询可及快、基因检测及时、结果发布及时,且与传统模式相比具有成本效益。
  • 该方法可在社区和学术机构以及不同癌症类型中推广。

研究设计与样本

  • 学术与产业合作创建简化工作流程,由Genome Medical提供多语言遗传咨询。
  • 试点项目评估有遗传性泌尿生殖系统综合征风险的患者,2020年1月1日至2022年1月7日期间所有需要胚系检测的患者接受混合式临床远程医疗检测前咨询,有指征时进行基因检测;根据结果提供检测后咨询,阳性者鼓励接受。

主要发现

  • 182例中146例(80.0%)同意参与,130例(89.0%)完成检测前咨询。
  • 中位年龄65岁(范围22-95),91%为男性,约60%患前列腺癌。
  • 从转诊至检测前咨询的中位时间为11天(IQR 7-20)。
  • 评估后127例(97.7%)被推荐检测,其中123例(96.8%)完成检测;从检测至结果发布的中位时间为15天(IQR 10-20.8)。
  • 40例(32.5%)接受了检测后咨询;私人保险报销逐年从17.2美元增至52.4美元;遗传咨询师满意度量表平均27.9分(满分30分)。

临床怎么用

  • 原文未据此给出具体临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To meet the increasing demands of genetic risk assessment for genitourinary cancers due to expanded clinical guidelines, we established an academic/industry partnership to create a streamlined workflow to overcome the barriers to access to care. MATERIALS AND METHODS: Genome Medical offers multilingual genetic counseling. A pilot program evaluated patients at risk for hereditary genitourinary syndromes. Between January 1, 2020 and January 07, 2022, all patients in need of germline testing were offered hybrid in-clinic telehealth pre-test counseling and when indicated, genetic testing. Post-test counseling was offered based on results and encouraged if positive. Testing results, patient satisfaction, and costs were evaluated. RESULTS: A total of 146 of 182 (80.0%) patients agreed to participate, with 130 (89.0%) completing pre-test counseling. Median age was 65 (range 22-95), with 91% being male and approximately 60% having prostate cancer. The median time from referral to pre-test counseling was 11 days (IQR 7-20). After assessment, testing was recommended for 127 (97.7%) of which 123 (96.8%) completed testing. The median time from testing to result release was 15 days (IQR 10-20.8). Forty (32.5%) had post-test counseling. Reimbursement by private insurers increased annually from $17.2 to $52.4. Patient satisfaction was high with a mean Genetic Counselor Satisfaction Scale of 27.9 out of 30. CONCLUSION: Our program provided high patient satisfaction, rapid access to genetic counseling, prompt genetic testing, timely release of results, and was cost-effective compared to traditional models. This approach is scalable across community and academic settings and across cancer types.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lin L, Lu E, Yurasits J, et al. Utilization of a Third-party Partnership in Tele-genetic Risk Assessment Program in Genitourinary Oncology. Urology. 2024. PMID: 38795832. doi:10.1016/j.urology.2024.05.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。